Loading stock data…
Savara Inc (SVRA)
$6.03+0.13 (+2.20%)
Market ClosedLast close Jun 29
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Savara Inc. in the Healthcare sector is trading at $6.03 with a market capitalization of $1.1B. Wall Street consensus targets $10.94 (8 analysts), implying a +81.4% move over the next 12 months. The stock is currently near its 52-week high of $7.00, remaining 17.1% above its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +81.4% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$38.14M↓ | -$33.42M↓ | -$30.25M↑ | -$31.44M↓ | -$27.65M |
| Net Income | -$37.28M↓ | -$32.24M↓ | -$29.56M↑ | -$30.40M↓ | -$26.64M |
Peer Comparison
JNJUNHPFE
Fundamentals
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.07B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-73.55%
Volume
Today's trading volume
1.44M
Recent News
What Savara Investors Should Know About This 580,187-Option Exercise and FDA Timeline
This clinical-stage biotech focused on rare lung diseases reported significant insider selling amid a year of strong share gains.
Assessing Savara (SVRA) Valuation As Shares Cool After Strong Long Term Returns
Recent share performance and business snapshot Savara (SVRA) has drawn attention after a period where the stock declined 3% over the past month and 9% over the past 3 months, despite a 114% total return over the past year. The clinical stage biopharmaceutical company, focused on rare respiratory diseases, has a market value of about US$1.29b and reported revenue of US$0 alongside a net loss of US$129.482m in its latest figures. See our latest analysis for Savara. At a share price of US$5.09,...
Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally
Vir Biotechnology develops immunology-based therapies targeting infectious diseases through global partnerships and scientific innovation.
Savara Inc. (SVRA) Reports Q1 Financial Results
Savara Inc. (NASDAQ:SVRA) is one of the 10 Best Penny Stocks to Buy for Long Term. On May 12, 2026, Savara Inc. (NASDAQ:SVRA) reported Q1 EPS of (15c), versus the consensus estimate of (14c). Chair and CEO Matt Pauls said the company ended the quarter with approximately $203M in cash and expects to have access […]
US High Growth Tech Stocks To Watch
The United States market remained flat over the last week, yet it has experienced a 30% rise over the past 12 months with earnings forecasted to grow by 16% annually. In this context of robust growth potential, identifying high-growth tech stocks involves focusing on companies that demonstrate strong innovation and adaptability to capitalize on emerging opportunities.